GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) is a 335-amino acid tetrameric enzyme (~37 kDa per subunit) encoded by the GAPDH gene on chromosome 12p13.31[@sirover2011]. While classically known as a glycolytic housekeeping enzyme, GAPDH has been extensively characterized as a moonlighting protein with critical non-glycolytic functions in [neurodegeneration](/diseases/neurodegeneration), including nuclear translocation–mediated [apoptosis](/mechanisms/apoptosis), [oxidative stress](/mechanisms/oxidative-stress) sensing, and direct interactions with disease-associated proteins such as [amyloid-beta](/proteins/amyloid-beta), [huntingtin](/proteins/huntingtin), and [alpha-synuclein](/proteins/alpha-synuclein)[@sirover2020]. Its dual identity as both an essential metabolic enzyme and a pro-death signal transducer makes it a nexus for understanding how energy metabolism and cell death intersect in neurodegenerative disease.
GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) is a 335-amino acid tetrameric enzyme (~37 kDa per subunit) encoded by the GAPDH gene on chromosome 12p13.31[@sirover2011]. While classically known as a glycolytic housekeeping enzyme, GAPDH has been extensively characterized as a moonlighting protein with critical non-glycolytic functions in [neurodegeneration](/diseases/neurodegeneration), including nuclear translocation–mediated [apoptosis](/mechanisms/apoptosis), [oxidative stress](/mechanisms/oxidative-stress) sensing, and direct interactions with disease-associated proteins such as [amyloid-beta](/proteins/amyloid-beta), [huntingtin](/proteins/huntingtin), and [alpha-synuclein](/proteins/alpha-synuclein)[@sirover2020]. Its dual identity as both an essential metabolic enzyme and a pro-death signal transducer makes it a nexus for understanding how energy metabolism and cell death intersect in neurodegenerative disease.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">GAPDH</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Glyceraldehyde-3-Phosphate Dehydrogenase</td></tr>
<tr><td><strong>Gene</strong></td><td>[GAPDH](/genes/gapdh)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P04406](https://www.uniprot.org/uniprot/P04406)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>[1ZNQ](https://www.rcsb.org/structure/1ZNQ), [4WNC](https://www.rcsb.org/structure/4WNC)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~37 kDa (monomer); ~148 kDa (tetramer)</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Cytoplasm; nucleus (under stress)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>GAPDH family (oxidoreductases)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">818 edges</a></td>
</tr>
</table>
</div>
GAPDH functions as a homotetramer, with each 335-residue subunit organized into two domains[@sirover2011]:
GAPDH catalyzes the reversible oxidative phosphorylation of G3P to 1,3-bisphosphoglycerate (1,3-BPG), coupling substrate oxidation to NAD+ reduction. This sixth step of glycolysis is the only energy-conserving oxidation in the pathway and generates both NADH and a high-energy acyl-phosphate bond. In [neurons](/entities/neurons), which derive approximately 90% of their ATP from oxidative phosphorylation, GAPDH-generated NADH feeds the malate–aspartate shuttle to sustain [mitochondrial](/mechanisms/mitochondrial-dysfunction) electron transport[@sirover2011].
GAPDH moonlights in at least six additional cellular processes[@sirover2020]:
The most direct pro-apoptotic function of GAPDH in neurodegeneration involves its interaction with the E3 ubiquitin ligase Siah1 (Seven in Absentia Homolog 1)[@hara2005]. Under conditions of oxidative or nitrosative stress:
This cascade has been demonstrated in cell models of [Huntington's disease](/diseases/huntingtons) (polyQ-expanded [huntingtin](/proteins/huntingtin) induces GAPDH nuclear accumulation), [Parkinson's disease](/diseases/parkinsons-disease) (MPTP/MPP+ drives GAPDH S-nitrosylation via nNOS), and [Alzheimer's disease](/diseases/alzheimers-disease) (Abeta oligomers increase GAPDH nuclear translocation in hippocampal neurons)[@burke1996][@mazzola2006].
Because the active-site Cys152 is extremely sensitive to [reactive oxygen species](/entities/reactive-oxygen-species) (ROS), GAPDH is among the first glycolytic enzymes inactivated during [oxidative stress](/mechanisms/oxidative-stress). In AD, PD, and [ALS](/diseases/als), post-mortem studies show 30–50% reductions in GAPDH activity in affected brain regions, correlating with lactate accumulation and energy crisis[@mazzola2001]. Paradoxically, transient GAPDH inactivation diverts glycolytic flux through the pentose phosphate pathway, generating NADPH to combat oxidative damage — a protective metabolic switch that may be overwhelmed in chronic neurodegeneration.
Under severe oxidative stress, GAPDH forms high-molecular-weight aggregates with amyloid-like cross-beta structure. These aggregates are cytotoxic and have been identified in post-mortem AD [cortex](/brain-regions/cortex), where they colocalize with [neurofibrillary tangles](/mechanisms/neurofibrillary-tangles). GAPDH aggregation is accelerated by the same conditions — elevated NO, ROS, and metal ions — that drive disease protein misfolding[@nakajima2009].
The MAO-B inhibitors [selegiline](/therapeutics/selegiline) (deprenyl) and [rasagiline](/therapeutics/rasagiline) were found to exert anti-apoptotic effects partly by blocking GAPDH–Siah1 binding and nuclear translocation, independent of their monoamine oxidase inhibition[@hara2005]. This "GAPDH-stabilizing" activity is thought to contribute to the neuroprotective signal observed in the DATATOP and ADAGIO trials in [PD](/diseases/parkinsons-disease).
CGP3466B is a deprenyl derivative specifically designed to block GAPDH nuclear translocation without MAO inhibitory activity. It showed neuroprotection in MPTP and SOD1-G93A mouse models but failed to reach efficacy endpoints in a Phase II/III [ALS](/diseases/als) trial, possibly due to advanced disease stage at enrollment[@miller2006].
Structure-activity studies identified the propargylamino pharmacophore as the critical moiety for disrupting the GAPDH–Siah1 interface. Several next-generation propargylamines (TCH346, ladostigil) retain GAPDH-stabilizing activity while adding additional mechanisms (cholinesterase inhibition, iron chelation) relevant to [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease).
Interactive diagram showing GAPDH key relationships in the SciDEX knowledge graph (15 connections shown).